GSK Leads Target-Validation Collaboration With EBI And Wellcome Trust
This article was originally published in The Pink Sheet Daily
Following its February participation in the NIH-led Accelerating Medicines Partnership, GSK now is joining with the European Bioinformatics Institute and Wellcome Trust Sanger Institute on a broad-based target-validation effort headquartered in the U.K. The collaboration’s work will be non-competitive and available to all.
You may also be interested in...
With $230 million from industry and NIH, the Accelerating Medicines Partnership will seek to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.
Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir.
As American auto giants GM and Ford take the wheel on working with ventilator manufacturers to make the critically needed devices during the COVID-19 pandemic, two longtime quality experts explain where the device and auto companies will find common ground when it comes to quality systems.